StockNews.com assumed coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a report issued on Saturday. The brokerage issued a sell rating on the biotechnology company’s stock.
Genocea Biosciences Stock Performance
The stock has a market capitalization of $6,000.00, a PE ratio of 0.00 and a beta of 1.61. Genocea Biosciences has a twelve month low of $0.00 and a twelve month high of $0.00. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.35 and a current ratio of 1.35.
Genocea Biosciences Company Profile
Featured Articles
- Five stocks we like better than Genocea Biosciences
- What is MarketRankā¢? How to Use it
- Tech Leader’s Stock Split: Is It the Right Time to Buy?
- What Are Dividend Champions? How to Invest in the Champions
- Could the Economy be Bottoming? Major Bank’s Earnings Say Yes
- Why Are These Companies Considered Blue Chips?
- Seize This Prime Stock Opportunity on Amazon Prime Days
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.